

# Yusuke Kawamura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/549414/publications.pdf>

Version: 2024-02-01

81  
papers

3,426  
citations

185998

28  
h-index

149479

56  
g-index

82  
all docs

82  
docs citations

82  
times ranked

3953  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir. <i>Hepatology Communications</i> , 2022, 6, 36-49.	2.0	14
2	Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib Treatment. <i>Internal Medicine</i> , 2022, , .	0.3	0
3	Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2022, 52, 153-164.	1.8	4
4	The useful predictors of zinc deficiency for the management of chronic liver disease. <i>Journal of Gastroenterology</i> , 2022, 57, 322-332.	2.3	5
5	Pretreatment Positron Emission Tomography with <sup>18</sup> F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2022, 100, 320-330.	0.9	5
6	Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease. <i>Hepatology International</i> , 2022, 16, 412-422.	1.9	2
7	Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study. <i>Hepatology Communications</i> , 2022, 6, 2286-2297.	2.0	20
8	Potential and Clinical Significance of <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment. <i>Oncology</i> , 2021, 99, 169-176.	0.9	6
9	TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Oncology</i> , 2021, 99, 114-123.	0.9	14
10	Potential of ultra-highly sensitive immunoassays for hepatitis B surface and core-related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Hepatology Research</i> , 2021, 51, 426-435.	1.8	21
11	Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease. <i>Hepatology Research</i> , 2021, 51, 62-68.	1.8	9
12	Pretreatment Positron Emission Tomography with <sup>18</sup> F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib Treatment. <i>Oncology</i> , 2021, 99, 611-621.	0.9	4
13	Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir. <i>Hepatology Research</i> , 2021, 51, 503-508.	1.8	6
14	Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. <i>Liver Cancer</i> , 2021, 10, 181-223.	4.2	307
15	Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs. <i>Journal of Gastroenterology</i> , 2021, 56, 1008-1021.	2.3	3
16	Comparison between Lumipulse Presto HBsAg-HQ and iTACT-HBsAg in Chronic Hepatitis B with Seroclearance of HBsAg by Architect HBsAg QT. <i>Acta Hepatologica Japonica</i> , 2021, 62, 667-668.	0.0	0
17	Histological impact at 5 years after the start of sodium-glucose cotransporter 2 inhibitor for non-alcoholic steatohepatitis complicated by diabetes mellitus. <i>Acta Hepatologica Japonica</i> , 2021, 62, 820-822.	0.0	0
18	Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease. <i>Internal Medicine</i> , 2020, 59, 329-338.	0.3	1

#	ARTICLE	IF	CITATIONS
19	Advantage of liver stiffness measurement before and after direct-acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C. <i>Hepatology Research</i> , 2020, 50, 426-438.	1.8	13
20	<sup>18</sup> F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib. <i>Liver Cancer</i> , 2020, 9, 84-92.	4.2	28
21	Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2020, 20, 368.	0.8	7
22	Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 756-770.	4.2	50
23	Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonography. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 1225-1232.	0.4	2
24	Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis. <i>Liver Cancer</i> , 2020, 9, 275-292.	4.2	34
25	SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology. <i>Internal Medicine</i> , 2020, 59, 1931-1937.	0.3	33
26	Long-term histological impact of sodium-glucose co-transporter-2 inhibitor for non-alcoholic steatohepatitis complicated by diabetes mellitus: 3 cases evaluated by liver histology at 3 years after the start of treatment. <i>Acta Hepatologica Japonica</i> , 2020, 61, 24-27.	0.0	1
27	Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. <i>Hepatology Research</i> , 2019, 49, 256-263.	1.8	12
28	Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan. <i>Journal of Gastroenterology</i> , 2019, 54, 182-193.	2.3	37
29	Long-term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapy. <i>Hepatology Research</i> , 2019, 49, 1441-1450.	1.8	11
30	Real-world effects of long-term rifaximin treatment for Japanese patients with hepatic encephalopathy. <i>Hepatology Research</i> , 2019, 49, 1406-1413.	1.8	11
31	Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 457-471.	1.9	58
32	Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus. <i>Hepatology Research</i> , 2019, 49, 531-539.	1.8	79
33	Primary liver carcinoma with sarcomatous changes: Analysis of 10 cases. <i>Hepatology Research</i> , 2019, 49, 711-717.	1.8	1
34	No-touch ablation in hepatocellular carcinoma has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resection. <i>Hepatology Research</i> , 2019, 49, 164-176.	1.8	21
35	Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b. <i>Journal of Medical Virology</i> , 2018, 90, 313-319.	2.5	51
36	Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan. <i>BMC Gastroenterology</i> , 2018, 18, 165.	0.8	27

#	ARTICLE	IF	CITATIONS
37	Usefulness and limitations of balloon-occluded transcatheter arterial chemoembolization using miriplatin for patients with four or fewer hepatocellular carcinoma nodules. <i>Hepatology Research</i> , 2017, 47, 338-346.	1.8	15
38	Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens. <i>Journal of Medical Virology</i> , 2017, 89, 1248-1254.	2.5	40
39	Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease. <i>Oncology</i> , 2017, 93, 92-98.	0.9	44
40	Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies. <i>Hepatology Communications</i> , 2017, 1, 46-52.	2.0	88
41	Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. <i>Journal of Medical Virology</i> , 2017, 89, 476-483.	2.5	111
42	Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs. <i>Journal of Gastroenterology</i> , 2017, 52, 641-651.	2.3	15
43	Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. <i>Journal of Medical Virology</i> , 2017, 89, 284-290.	2.5	50
44	Potential of a touch pincer ablation procedure that uses a multipolar radiofrequency ablation system to prevent intrasubsegmental recurrence of small and single hepatocellular carcinomas. <i>Hepatology Research</i> , 2017, 47, 1008-1020.	1.8	19
45	New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease. <i>Internal Medicine</i> , 2017, 56, 1459-1465.	0.3	2
46	Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2017, 11, 674-683.	1.4	12
47	Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2016, 16, 141.	0.8	32
48	Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan. <i>Hepatology International</i> , 2016, 10, 647-656.	1.9	35
49	Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma. <i>Oncology</i> , 2016, 90, 167-175.	0.9	9
50	Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 597-605.	2.4	26
51	Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan. <i>Gut and Liver</i> , 2016, 10, 437-45.	1.4	29
52	Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection. <i>Virology Journal</i> , 2015, 12, 225.	1.4	10
53	New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan. <i>Hepatology International</i> , 2015, 9, 269-277.	1.9	8
54	Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir. <i>Drug Design, Development and Therapy</i> , 2014, 8, 869.	2.0	9

#	ARTICLE	IF	CITATIONS
55	Potential of a no-touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: An experimental animal study. <i>Hepatology Research</i> , 2014, 44, 1234-1240.	1.8	17
56	In Hepatocellular Carcinomas, any Proportion of Poorly Differentiated Components is Associated with Poor Prognosis After Hepatectomy. <i>World Journal of Surgery</i> , 2014, 38, 1147-1153.	0.8	21
57	Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis. <i>Hepatology International</i> , 2013, 7, 850-858.	1.9	6
58	Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study. <i>Journal of Gastroenterology</i> , 2013, 48, 930-941.	2.3	52
59	Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. <i>Hepatology</i> , 2013, 58, 98-107.	3.6	596
60	Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma. <i>Hepatology Research</i> , 2013, 43, 942-949.	1.8	20
61	Amino Acid Substitutions in the Hepatitis C Virus Core Region and Lipid Metabolism Are Associated with Hepatocarcinogenesis in Nonresponders to Interferon plus Ribavirin Combination Therapy. <i>Intervirology</i> , 2013, 56, 13-21.	1.2	14
62	Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2013, 43, 1163-1168.	1.8	30
63	Transcatheter Arterial Chemotherapy Using Miriplatin-Lipiodol Suspension with or without Embolization for Unresectable Hepatocellular Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 175-182.	0.6	15
64	Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2012, 107, 253-261.	0.2	230
65	Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2012, 57, 508-514.	1.8	153
66	Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 2012, 84, 1199-1207.	2.5	9
67	Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. <i>Journal of Gastroenterology</i> , 2012, 47, 814-822.	2.3	20
68	Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. <i>Hepatology Research</i> , 2012, 42, 264-272.	1.8	47
69	Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <math>\leq 126\text{ mg/dL}</math>. <i>Hepatology Research</i> , 2012, 42, 558-563.	1.8	7
70	Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus. <i>Hepatology Research</i> , 2011, 41, 524-529.	1.8	23
71	Heterogeneous Type 4 Enhancement of Hepatocellular Carcinoma on Dynamic CT Is Associated With Tumor Recurrence After Radiofrequency Ablation. <i>American Journal of Roentgenology</i> , 2011, 197, W665-W673.	1.0	51
72	Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus. <i>Journal of Medical Virology</i> , 2010, 82, 390-395.	2.5	34

#	ARTICLE	IF	CITATIONS
73	HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. <i>Liver International</i> , 2010, 30, 1461-1470.	1.9	67
74	Diabetes Enhances Hepatocarcinogenesis in Noncirrhotic, Interferon-treated Hepatitis C Patients. <i>American Journal of Medicine</i> , 2010, 123, 951-956.e1.	0.6	31
75	New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma. <i>Hepatology Research</i> , 2010, 40, 1006-1014.	1.8	62
76	Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. <i>Hepatology</i> , 2009, 49, 739-744.	3.6	234
77	Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin. <i>Hepatology Research</i> , 2009, 39, 346-354.	1.8	23
78	Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1739-1746.	1.4	44
79	The Efficacy of Short-term Interferon-beta Therapy for Chronic Hepatitis C Patients with Low Virus Load. <i>Internal Medicine</i> , 2008, 47, 355-360.	0.3	4
80	Hepatocarcinogenesis Following HCV RNA Eradication by Interferon in Chronic Hepatitis Patients. <i>Internal Medicine</i> , 2008, 47, 1637-1643.	0.3	42
81	Viral Elimination Reduces Incidence of Malignant Lymphoma in Patients with Hepatitis C. <i>American Journal of Medicine</i> , 2007, 120, 1034-1041.	0.6	123